Human Movement Laboratory, São Judas Tadeu University, São Paulo/SP, Brazil.
Aging Male. 2013 Sep;16(3):85-91. doi: 10.3109/13685538.2013.801952. Epub 2013 Jun 12.
Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). A patent was registered for this drug in 1990, which expired in 2010. Since expiration, the drug has been marketed under various trade names or as generic drugs. Numerous clinical trials have been conducted addressing the effectiveness of the drug for erectile dysfunction (ED) and its safety regarding the presence or absence of specific comorbidities. After over 20 years in the market, we need to ask: has the scientific community reached a general consensus as to the overall efficacy and safety of the drug? Can we firmly state that the benefits of the drug outweigh its risks? This review suggests that sildenafil is an effective and easily manageable treatment for erectile dysfunction, both in the absence and in the presence of comorbidities. After two decades of the emergence of sildenafil as a drug of choice for the treatment of ED (and the numerous studies and clinical trials undertaken during this time span), it is now possible to state that the benefits of the drug do outweigh the risks, and represent an significant improvement in the quality of life in men with ED.
西地那非是一种环磷酸鸟苷（cGMP）特异性磷酸二酯酶 5（PDE-5）的选择性抑制剂。该药物于 1990 年注册专利，并于 2010 年到期。自专利过期以来，该药物已以各种商品名或仿制药形式上市。已经进行了许多临床试验，以评估该药物对勃起功能障碍（ED）的有效性及其在存在或不存在特定合并症时的安全性。在市场上销售 20 多年后，我们需要问：科学界是否就该药物的总体疗效和安全性达成了普遍共识？我们能否肯定地说，该药物的益处超过其风险？本综述表明，西地那非是一种有效且易于管理的勃起功能障碍治疗方法，无论是在没有合并症的情况下还是在存在合并症的情况下。西地那非作为 ED 治疗的首选药物出现了二十多年（在此期间进行了许多研究和临床试验）之后，现在可以说，该药物的益处超过了风险，并且代表着 ED 男性生活质量的重大改善。
